Curcumin improves MMC-based chemotherapy by simultaneously sensitising cancer cells to MMC and reducing MMC-associated side-effects

Qian Mei Zhou, Xiu Feng Wang, Xin Jun Liu, Hui Zhang, Yi Yu Lu, Shuang Huang, Shi Bing Su

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Mitomycin C (MMC) potently suppresses tumour growth. However, its use is limited by its severe toxicity to the kidney and bone marrow. The purpose of this study is to investigate whether the chemoprevention agent curcumin can reduce MMC-associated side-effects and improve MMC efficacy in a breast cancer xenograft model. We first determined the effectiveness of combined MMC and curcumin to inhibit in vitro cell growth and to regress in vivo tumour outgrowth. We then investigated the mechanisms associated with MMC/curcumin-induced cell death by examining the effect of MMC/curcumin treatment on apoptosis, the activation of caspase-3, 8 and 9 and the expression of bcl-2 and bax. We also evaluated the ability of curcumin to alleviate MMC-associated side-effects by comparing the levels of creatinine/blood urea nitrogen (Cr/BUN) and glutamic oxalacetic transaminase/glutamic pyruvic transaminase (GPT/GOT) in serum between animals receiving MMC alone and MMC/curcumin. Curcumin significantly sensitised MCF-7 and MDA-MB-231 cells to MMC-induced cell death and improved MMC's ability to regress MCF-7 xenograft. MMC and curcumin together synergistically enhanced apoptosis in MCF-7 cells and the apoptosis most likely resulted from both the activation of caspases and modulation of bcl-2/bax expression. Most importantly, the inclusion of curcumin in MMC treatment decreased MMC-caused severe side-effects evidenced by significant improvement in the kidney function. Enhancing the tumoricidal effect of MMC, curcumin greatly reduces MMC-associated severe side-effects. Therefore, the combination treatment of MMC and curcumin may be of significant therapeutic benefit in treating breast cancer.

Original languageEnglish (US)
Pages (from-to)2240-2247
Number of pages8
JournalEuropean Journal of Cancer
Volume47
Issue number14
DOIs
StatePublished - Sep 1 2011

Fingerprint

Curcumin
Mitomycin
Drug Therapy
Neoplasms
Apoptosis
Heterografts
Cell Death
Breast Neoplasms
Kidney
Caspase 9
Caspase 8
Blood Urea Nitrogen
MCF-7 Cells
Chemoprevention
Therapeutics
Growth
Caspases
Transaminases
Alanine Transaminase

Keywords

  • Combination
  • Curcumin
  • Mitomycin C
  • Side-effects

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Curcumin improves MMC-based chemotherapy by simultaneously sensitising cancer cells to MMC and reducing MMC-associated side-effects. / Zhou, Qian Mei; Wang, Xiu Feng; Liu, Xin Jun; Zhang, Hui; Lu, Yi Yu; Huang, Shuang; Su, Shi Bing.

In: European Journal of Cancer, Vol. 47, No. 14, 01.09.2011, p. 2240-2247.

Research output: Contribution to journalArticle

Zhou, Qian Mei ; Wang, Xiu Feng ; Liu, Xin Jun ; Zhang, Hui ; Lu, Yi Yu ; Huang, Shuang ; Su, Shi Bing. / Curcumin improves MMC-based chemotherapy by simultaneously sensitising cancer cells to MMC and reducing MMC-associated side-effects. In: European Journal of Cancer. 2011 ; Vol. 47, No. 14. pp. 2240-2247.
@article{86667c89d6c74bac951243a69b6c8f41,
title = "Curcumin improves MMC-based chemotherapy by simultaneously sensitising cancer cells to MMC and reducing MMC-associated side-effects",
abstract = "Mitomycin C (MMC) potently suppresses tumour growth. However, its use is limited by its severe toxicity to the kidney and bone marrow. The purpose of this study is to investigate whether the chemoprevention agent curcumin can reduce MMC-associated side-effects and improve MMC efficacy in a breast cancer xenograft model. We first determined the effectiveness of combined MMC and curcumin to inhibit in vitro cell growth and to regress in vivo tumour outgrowth. We then investigated the mechanisms associated with MMC/curcumin-induced cell death by examining the effect of MMC/curcumin treatment on apoptosis, the activation of caspase-3, 8 and 9 and the expression of bcl-2 and bax. We also evaluated the ability of curcumin to alleviate MMC-associated side-effects by comparing the levels of creatinine/blood urea nitrogen (Cr/BUN) and glutamic oxalacetic transaminase/glutamic pyruvic transaminase (GPT/GOT) in serum between animals receiving MMC alone and MMC/curcumin. Curcumin significantly sensitised MCF-7 and MDA-MB-231 cells to MMC-induced cell death and improved MMC's ability to regress MCF-7 xenograft. MMC and curcumin together synergistically enhanced apoptosis in MCF-7 cells and the apoptosis most likely resulted from both the activation of caspases and modulation of bcl-2/bax expression. Most importantly, the inclusion of curcumin in MMC treatment decreased MMC-caused severe side-effects evidenced by significant improvement in the kidney function. Enhancing the tumoricidal effect of MMC, curcumin greatly reduces MMC-associated severe side-effects. Therefore, the combination treatment of MMC and curcumin may be of significant therapeutic benefit in treating breast cancer.",
keywords = "Combination, Curcumin, Mitomycin C, Side-effects",
author = "Zhou, {Qian Mei} and Wang, {Xiu Feng} and Liu, {Xin Jun} and Hui Zhang and Lu, {Yi Yu} and Shuang Huang and Su, {Shi Bing}",
year = "2011",
month = "9",
day = "1",
doi = "10.1016/j.ejca.2011.04.032",
language = "English (US)",
volume = "47",
pages = "2240--2247",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Limited",
number = "14",

}

TY - JOUR

T1 - Curcumin improves MMC-based chemotherapy by simultaneously sensitising cancer cells to MMC and reducing MMC-associated side-effects

AU - Zhou, Qian Mei

AU - Wang, Xiu Feng

AU - Liu, Xin Jun

AU - Zhang, Hui

AU - Lu, Yi Yu

AU - Huang, Shuang

AU - Su, Shi Bing

PY - 2011/9/1

Y1 - 2011/9/1

N2 - Mitomycin C (MMC) potently suppresses tumour growth. However, its use is limited by its severe toxicity to the kidney and bone marrow. The purpose of this study is to investigate whether the chemoprevention agent curcumin can reduce MMC-associated side-effects and improve MMC efficacy in a breast cancer xenograft model. We first determined the effectiveness of combined MMC and curcumin to inhibit in vitro cell growth and to regress in vivo tumour outgrowth. We then investigated the mechanisms associated with MMC/curcumin-induced cell death by examining the effect of MMC/curcumin treatment on apoptosis, the activation of caspase-3, 8 and 9 and the expression of bcl-2 and bax. We also evaluated the ability of curcumin to alleviate MMC-associated side-effects by comparing the levels of creatinine/blood urea nitrogen (Cr/BUN) and glutamic oxalacetic transaminase/glutamic pyruvic transaminase (GPT/GOT) in serum between animals receiving MMC alone and MMC/curcumin. Curcumin significantly sensitised MCF-7 and MDA-MB-231 cells to MMC-induced cell death and improved MMC's ability to regress MCF-7 xenograft. MMC and curcumin together synergistically enhanced apoptosis in MCF-7 cells and the apoptosis most likely resulted from both the activation of caspases and modulation of bcl-2/bax expression. Most importantly, the inclusion of curcumin in MMC treatment decreased MMC-caused severe side-effects evidenced by significant improvement in the kidney function. Enhancing the tumoricidal effect of MMC, curcumin greatly reduces MMC-associated severe side-effects. Therefore, the combination treatment of MMC and curcumin may be of significant therapeutic benefit in treating breast cancer.

AB - Mitomycin C (MMC) potently suppresses tumour growth. However, its use is limited by its severe toxicity to the kidney and bone marrow. The purpose of this study is to investigate whether the chemoprevention agent curcumin can reduce MMC-associated side-effects and improve MMC efficacy in a breast cancer xenograft model. We first determined the effectiveness of combined MMC and curcumin to inhibit in vitro cell growth and to regress in vivo tumour outgrowth. We then investigated the mechanisms associated with MMC/curcumin-induced cell death by examining the effect of MMC/curcumin treatment on apoptosis, the activation of caspase-3, 8 and 9 and the expression of bcl-2 and bax. We also evaluated the ability of curcumin to alleviate MMC-associated side-effects by comparing the levels of creatinine/blood urea nitrogen (Cr/BUN) and glutamic oxalacetic transaminase/glutamic pyruvic transaminase (GPT/GOT) in serum between animals receiving MMC alone and MMC/curcumin. Curcumin significantly sensitised MCF-7 and MDA-MB-231 cells to MMC-induced cell death and improved MMC's ability to regress MCF-7 xenograft. MMC and curcumin together synergistically enhanced apoptosis in MCF-7 cells and the apoptosis most likely resulted from both the activation of caspases and modulation of bcl-2/bax expression. Most importantly, the inclusion of curcumin in MMC treatment decreased MMC-caused severe side-effects evidenced by significant improvement in the kidney function. Enhancing the tumoricidal effect of MMC, curcumin greatly reduces MMC-associated severe side-effects. Therefore, the combination treatment of MMC and curcumin may be of significant therapeutic benefit in treating breast cancer.

KW - Combination

KW - Curcumin

KW - Mitomycin C

KW - Side-effects

UR - http://www.scopus.com/inward/record.url?scp=80052528373&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052528373&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2011.04.032

DO - 10.1016/j.ejca.2011.04.032

M3 - Article

VL - 47

SP - 2240

EP - 2247

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 14

ER -